Rusfertide

Sep 04, 2026

Summary On August 28, 2026, the FDA approved MIMRYLO (rusfertide), developed by Protagonist Therapeutics and commercialized by Takeda, for treating erythrocytosis in adults with polycythemia vera. MIMRYLO is the first approved hepcidin mimetic peptide for PV. It targets the iron-regulation pathway rather tha...

Jul 10, 2025

JAKAFI’s demand continues to grow in Polycythemia Vera The therapeutic paradigm for polycythemia vera treatment has evolved notably in recent years. Historically managed with generics like aspirin, hydroxyurea, phlebotomy, and interferons, the landscape shifted dramatically with the FDA approval of JAKAFI (rux...